Market Mayhem: Stocks in the Spotlight!
Market Mayhem: Three Fresh Knife Fights (Oct 26, 2025)
The tape’s a roller coaster, the takes are feral, and your broker’s phone is on mute. Here are three stocks that split the room today—both sides, then a clean, first‑principles read to keep your P&L out of the wood chipper.
1) Apple (AAPL): “Fortress cash machine” vs “Oops‑we‑invented the iPhone Mini again”
Why it’s loud
- Multiple outlets say Apple is slashing iPhone Air production toward “end‑of‑production” levels just weeks after launch, shifting build to iPhone 17 and 17 Pro. Ming‑Chi Kuo pegs supply chain cuts at 80% into early 2026. (macrumors.com)
Bull case (this is fine gif)
- Mix shift might actually improve margins: consumers are gravitating to base and Pro models with better willingness to pay, keeping total iPhone 17 production roughly on plan. Apple’s ecosystem and services ARPU shrug at one flop like it’s a fly on the windshield. (theverge.com)
Bear case (design diet, battery starvation)
- iPhone Air’s value prop—thin and pretty—got pantsed by one camera and meh battery. If Apple mis‑forecast demand, channel cleanup and supplier de‑commit fees can nick GM% and stoke “has Cupertino lost the magic?” think‑pieces into earnings. (techradar.com)
My take, first principles (lineup economics)
- Phones are a portfolio. If a SKU face‑plants, two questions matter: does total unit mix stay in the money, and do services attach rates hold? Early read says yes on both. The risk is narrative: a hyped SKU dying fast can haircut multiple until Apple proves holiday sell‑through. I’m buying fear if we get a knee‑jerk margin scare, but I want: (1) concrete Q4 guidance on iPhone mix, (2) any disclosure on supplier penalties, (3) Services growth > high‑teens to smother the hardware noise. (macrumors.com)
2) MicroStrategy (MSTR): “Levered BTC alpha” vs “dilution geyser with a logo”
Why it’s loud
- Bitcoin sits around $113.7k today, keeping MSTR in the headlines as the de facto public BTC call‑option. The company rebranded earlier this year to shout the strategy from rooftops, and the street can’t decide if that’s conviction or cosplay. (reuters.com)
Bull case (Saylor’s religion)
- Massive BTC stack + corporate wrapper = volatility‑juiced proxy for a secular crypto bid. If spot BTC rips, MSTR’s premium to NAV can expand on reflex, and the treasury playbook has historically weaponized equity to buy more coins on rips and dips. (reuters.com)
Bear case (math sobers up)
- Chronic dilution, negative operating metrics, and new accounting transparency make the equity a piñata when BTC wobbles. Class‑action chatter and articles highlighting unrealized losses and dependency on capital markets add tinder. If liquidity tightens, forced selling risk isn’t theoretical. (tradingnews.com)
My take, first principles (NAV, leverage, reflexivity)
- Treat MSTR like a closed‑end fund with an activist CEO, a software side hustle, and a tolerance for dilution that would make a SPAC blush. Your thesis must be: (1) BTC up and to the right, (2) capital markets remain open, (3) premium to NAV doesn’t compress when you need it least. Otherwise, just buy BTC and keep your share count. If you must tango, size it like an option and watch BTC drawdown bands like a hawk.
3) Eli Lilly (LLY): “GLP‑1 empire” vs “DC with a price machete”
Why it’s loud
- Fresh policy jawboning aimed at GLP‑1 prices whacked the group last week; Lilly’s also dealing with a big False Claims Act loss on appeal and some pipeline pruning. Meanwhile, it’s cutting self‑pay prices for Zepbound to blunt coverage cliffs. The bulls and bears are throwing chairs. (markets.financialcontent.com)
Bull case (volume cures a lot)
- Demand is a tidal wave; lower self‑pay prices via LillyDirect and new vial options extend reach. Even if list prices get a haircut, volume, duration, and next‑gen orals can keep the cash volcano flowing—especially as compounded copycats get squeezed. (investopedia.com)
Bear case (policy/payer pincer)
- The “$150 Ozempic” political drumbeat pressures net price across the class; insurers are already slamming doors for 2026 coverage. Add a $183.7M Medicaid judgment optics hit and binned combo trial, and the multiple could catch the flu. (markets.financialcontent.com)
My take, first principles (net price x persistence x capacity)
- GLP‑1 profitability is a triangle: net price, adherence, and manufacturing scale. Lilly’s best defense is insane scale and superior outcomes data; its worst enemy is broad payer exclusions that nuke persistence. I want: (1) 2026 coverage updates from top PBMs, (2) orforglipron/next‑gen readouts that justify “best‑in‑class” stickiness, (3) proof that self‑pay channels can replace employer coverage leakage without torching margin. Great business—buy policy panics, sell euphoria. (zacks.com)
Tape‑Side Tactics (aka, how not to blow a hamstring)
- AAPL: Fade the “Air is dead, Apple is doomed” think‑pieces into any margin‑panic dip if Services stays hot and 17/Pro mix carries. Watch for supplier penalty disclosures on the call. (macrumors.com)
- MSTR: Position like a call on BTC with greeks you can’t see. If BTC < key bands, expect premium‑to‑NAV compression and dilution headlines. Small, tactical, stop‑disciplined.
- LLY: Scale in on policy fear and legal‑headline pukes; reassess if major PBMs formalize 2026 exclusions or if net price erosion outruns volume gains. (reuters.com)
Not investment advice. This is Wall Street—where hope is a four‑letter word, and your portfolio doesn’t care about your feelings.